Zeta Corporation is an ISO 13485:2016 and FDA registered biomedical company that manufactures and distributes IVD antibodies for Pathology/IHC. We provide the highest quality of antibodies to help pathologists diagnose human tumors and diseases. Zeta antibodies are carefully curated to produce reproducible results on formalin-fixed, paraffin-embedded (FFPE) sections manually or using commercially available automated equipment. Zeta utilizes its collective knowledge of over 75 years to validate and standardize every antibody individually for immunohistochemistry (IHC) application. Zeta designs and develops tumor-specific biomarkers using cutting-edge technology to uniquely select the immunogens for our famed RAbMono™ (Rabbit Monoclonal) and MonoMAb™ (Monospecific monoclonal antibodies). Zeta’s MonoMAb™ and RAbMono™ Antibodies are produced through hybridoma and recombinant technologies. MonoMAb™: The clones are first screened by ELISA and gel electrophoresis to determine their specificity. The selected antibodies are further screened by staining FFPE sections. Only those antibodies that worked on FFPE sections are selected for further protein array analysis to select the highly specific clones for IHC. RAbMono™: Rabbit monoclonal primary antibodies are designed and developed by Zeta’s accomplished scientists and validated to perform with high sensitivity and specificity. It is our commitment to produce and release several primary antibodies for the routine and unique targets. We are proud of our commitment to producing highly specific, target-validated, and characterized IVD primary biomarkers to aid pathologists in the differential diagnosis of various tumors. Zeta Corporation sells the products directly in the US and distributes them to over 50 different countries globally through our trusted partners. Zeta offers CE-IVD labeled products with European regulatory compliance and encourages distributors to register the products in the individual territories.
View Top Employees from Zeta Corporation - Target-validated and Characterized Monoclonal Antibody CompanyWebsite | https://www.zeta-corp.com/ |
Revenue | $5.4 million |
Employees | 5 (5 on RocketReach) |
Founded | 2003 |
Address | 65 N 1st Ave # 202C, Arcadia, California 91006, US |
Phone | (626) 355-2053 |
Industry | Biotechnology Research, Manufacturing General, Manufacturing |
Competitors | Genemed Synthesis Inc, ProMab Biotechnologies, Inc., SouthernBiotech, exonbio |
SIC | SIC Code 80 Companies, SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 33 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company employee's phone or email?
The Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company annual revenue was $5.4 million in 2024.
Xiyong Liu is the Laboratory Director of Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company.
5 people are employed at Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company.
Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company is based in Arcadia, California.
The NAICS codes for Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company are [33, 3254, 325, 32].
The SIC codes for Zeta Corporation - Target-validated and Characterized Monoclonal Antibody Company are [80, 283, 28].